| 2025-11-06 |
详情>>
股本变动：
变动后总股本4457.97万股
变动原因 ▼▲
- 原因：
- From June 30, 2025 to September 30, 2025
Vesting of restricted stock units
Shares withheld for taxes
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.22美元,归母净利润-5385.3万美元,同比去年增长-333.49%
|
| 2025-11-06 |
财报披露：
美东时间 2025-11-06 盘前发布财报
|
| 2025-09-05 |
详情>>
内部人交易：
DENELSKY STEPHEN J股份增加110000.00股
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-1.19美元,归母净利润-5262.2万美元,同比去年增长-590.49%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-1.14美元,归母净利润-5034万美元,同比去年增长-972.43%
|
| 2025-04-21 |
股东大会：
将于2025-06-02召开股东大会
会议内容 ▼▲
- 1.The election of one Class I Director named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2028 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
4.Approval of the Harvard Bioscience, Inc. Amended and Restated 2021 Incentive Plan to increase the number of authorized shares of Common Stock available for issuance thereunder;
5.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2025-03-14 |
详情>>
业绩披露：
2024年年报每股收益-0.28美元,归母净利润-1240.5万美元,同比去年增长-263.25%
|
| 2024-11-08 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.29美元,归母净利润-1242.3万美元,同比去年增长-677.9%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.18美元,归母净利润-762.1万美元,同比去年增长-2028.77%
|
| 2024-05-07 |
详情>>
业绩披露：
2024年一季报每股收益-0.11美元,归母净利润-469.4万美元,同比去年增长-854.66%
|
| 2024-04-03 |
股东大会：
将于2024-05-14召开股东大会
会议内容 ▼▲
- 1.The election of one Class III Director named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2027 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
4.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2024-03-07 |
详情>>
业绩披露：
2023年年报每股收益-0.08美元,归母净利润-341.5万美元,同比去年增长64.11%
|
| 2023-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.04美元,归母净利润-159.7万美元,同比去年增长79.66%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.01美元,归母净利润-35.8万美元,同比去年增长91.95%
|
| 2023-04-05 |
股东大会：
将于2023-05-15召开股东大会
会议内容 ▼▲
- 1.The election of two Class II Directors named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2026 and until such Director’s successor is duly elected and qualified or until his or her earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
4.Recommendation, by a non-binding advisory vote, of the frequency (one, two or three years) of the shareholder vote to approve the compensation of the Company’s named executive officers;
5.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2022-04-07 |
股东大会：
将于2022-05-17召开股东大会
会议内容 ▼▲
- 1.The election of two Class I Directors named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2025 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.Adoption and approval of an amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of common stock available for issuance by 500,000 shares of common stock;
4.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
5.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-08 |
股东大会：
将于2021-05-18召开股东大会
会议内容 ▼▲
- 1.The election of one Class III Director named in the accompanying proxy statement, nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2024 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.Adoption and approval of the Harvard Bioscience, Inc. 2021 Incentive Plan;
4.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
5.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2020-04-28 |
股东大会：
将于2020-06-11召开股东大会
会议内容 ▼▲
- 1.The election of two Class II Directors named in the accompanying proxy statement, each nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2023 and until such Director’s successor is duly elected and qualified or until his or her earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.Approval of the Harvard Bioscience, Inc. Fourth Amended and Restated 2000 Stock Option and Incentive Plan to, among other things, increase the number of authorized shares of Common Stock available for issuance thereunder by 3,700,000 and to reduce the fungible share ratio thereunder;
4.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
5.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2019-04-05 |
股东大会：
将于2019-05-16召开股东大会
会议内容 ▼▲
- 1.The election of two Class I Directors, each nominated by the Board of Directors for a three-year term, such term to continue until the annual meeting of stockholders in 2022 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.Approval of an amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares of Common Stock available for issuance by 350,000 shares of Common Stock;
4.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
5.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2018-04-06 |
股东大会：
将于2018-05-17召开股东大会
会议内容 ▼▲
- 1.The election of one Class III Director, nominated by the Board of Directors, for a three-year term, such term to continue until the annual meeting of stockholders in 2021 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal;
2.The ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.Approval of an amendment to the Harvard Bioscience, Inc. Third Amended and Restated 2000 Stock Option and Incentive Plan to increase the number of authorized shares of Common Stock available for issuance by 3,400,000 shares of Common Stock;
4.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
5.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2017-04-05 |
股东大会：
将于2017-05-18召开股东大会
会议内容 ▼▲
- 1.The election of one Class II Director, nominated by the Board of Directors, for a three-year term, such term to continue until the annual meeting of stockholders in 2020 and until such Director’s successor is duly elected and qualified or until his earlier resignation or removal;
2.The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
3.Approval of an amendment to the Harvard Bioscience, Inc. Employee Stock Purchase Plan to increase the number of authorized shares available for issuance by 300,000 shares of common stock;
4.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
5.Recommendation, by a non-binding advisory vote, of the frequency (one, two or three years) of the shareholder vote to approve the compensation of Harvard Bioscience’s named executive officers;
6.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|
| 2016-05-12 |
股东大会：
将于2016-06-24召开股东大会
会议内容 ▼▲
- 1.The election of two Class I Directors, nominated by the Board of Directors (or the “Board”), for three-year terms, such terms to continue until the annual meeting of stockholders in 2019 and until such Directors’ successors are duly elected and qualified or until their earlier resignation or removal;
2.The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2016;
3.Approval, by a non-binding advisory vote, of the compensation of our named executive officers;
4.Such other business as may properly come before the Annual Meeting and any adjournments or postponements thereof.
|